ICU
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E N/A, P/S 12.01, Graham Number None
- Price/Book ratio is relatively low at 1.37
- P/S ratio of 12.01 is expensive for a loss-making micro-cap
- No Graham Number or Intrinsic Value available due to lack of earnings
Ref Revenue Growth 526.90%, EPS Growth +91.1%
- Revenue growth > 500%
- EPS is trending upward (less negative)
- Analyst target price of $9.00 suggests significant upside
- Sustainability of growth without a path to profitability
Ref Historical Price Performance
- Recent 1-month bounce of +33.9%
- 5-year return of -99.8%
- 1-year return of -70.8%
Ref Piotroski F-Score 0/9, Altman Z-Score None
- Low Debt/Equity (0.05)
- Strong Current Ratio (3.63)
- Piotroski F-Score 0/9 indicates total fundamental weakness
- Negative ROE and ROA
Ref Dividend Yield N/A
- No dividend paid
- No history of payouts
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for ICU and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
ICU
SeaStar Medical Holding Corporation
Primary
|
-99.8% | -99.3% | -70.8% | -35.1% | +33.9% | -13.9% |
|
HKPD
Cellyan Biotechnology Co., Ltd
Peer
|
-77.9% | -77.9% | -40.8% | -47.7% | -1.0% | +9.3% |
|
BMGL
Basel Medical Group Ltd
Peer
|
-82.0% | -82.0% | -82.0% | -64.4% | +23.8% | -3.5% |
|
CYCN
Cyclerion Therapeutics, Inc.
Peer
|
-93.9% | -46.5% | +40.9% | +36.5% | +133.6% | +124.5% |
|
HIND
Vyome Holdings, Inc.
Peer
|
-100.0% | -100.0% | -96.1% | -56.8% | -15.1% | +2.8% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
ICU
SeaStar Medical Holding Corporation
|
BEARISH | $14.82M | - | -295.2% | -% | $3.71 | |
|
HKPD
Cellyan Biotechnology Co., Ltd
|
BEARISH | $14.62M | - | -13.4% | -4.3% | $0.62 | Compare |
|
BMGL
Basel Medical Group Ltd
|
BEARISH | $15.03M | - | -194.6% | -99.8% | $0.8 | Compare |
|
CYCN
Cyclerion Therapeutics, Inc.
|
BEARISH | $15.07M | - | -39.3% | -170.1% | $3.48 | Compare |
|
HIND
Vyome Holdings, Inc.
|
BEARISH | $15.37M | - | -% | -% | $2.19 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2025-12-19 | BAIRD JENNIFER A | Director | Purchase | 4,200 | $987 |
| 2025-12-09 | MESSINGER MICHAEL | Chief Financial Officer | Purchase | 14,500 | $5,098 |
Past News Coverage
Recent headlines mentioning ICU from our newsroom.